KTTA earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -0.19. Updated 2026-07-23.
Pasithea Therapeutics (KTTA) Research Hub
Pasithea Therapeutics (KTTA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.53 USD (-6.97%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.19, market cap 0.00B. This hub links to the full technical, earnings and options research available for KTTA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.53 USD (-6.97%) |
| 52-week range | 0.4219 USD – 0.6044 USD |
| Trend regime | Range |
| 14-day RSI | 54.8 (Neutral) |
| Trailing P/E | -0.19 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for KTTA
Covered Call on KTTA: how it works, illustrative setup around the real 0.53 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KTTA: how it works, illustrative setup around the real 0.53 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KTTA: how it works, illustrative setup around the real 0.53 USD price, max profit/loss, breakeven and when to use it. Educational.
KTTA technical analysis: range, last 0.53 USD, RSI 54.8, 52w range 0.4219 USD–0.6044 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is KTTA in?
Pasithea Therapeutics (KTTA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is KTTA in an uptrend or downtrend?
As of 2026-09-11, KTTA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KTTA's trailing P/E ratio?
KTTA's trailing P/E is -0.19, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does KTTA next report earnings?
KTTA is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.16 USD.